137 related articles for article (PubMed ID: 32813334)
1. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India.
Dhingra H; Kalra M; Mahajan A
Pediatr Blood Cancer; 2020 Nov; 67(11):e28394. PubMed ID: 32813334
[TBL] [Abstract][Full Text] [Related]
2. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
3. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.
Kapoor G; Sinha R; Abedin S
Pediatr Blood Cancer; 2012 Sep; 59(3):448-53. PubMed ID: 22271707
[TBL] [Abstract][Full Text] [Related]
4. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
5. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
[TBL] [Abstract][Full Text] [Related]
6. Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate.
Tiwari P; Thomas MK; Pathania S; Dhawan D; Gupta YK; Vishnubhatla S; Bakhshi S
Pediatr Hematol Oncol; 2015; 32(8):576-84. PubMed ID: 26558505
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
Skarin AT; Canellos GP
NCI Monogr; 1987; (5):71-6. PubMed ID: 3501548
[TBL] [Abstract][Full Text] [Related]
8. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
9. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
[TBL] [Abstract][Full Text] [Related]
12. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
13. Effect of high-dose methotrexate on plasma hypoxanthine and uridine levels in patients with acute leukemia or non-Hodgkin lymphoma in childhood.
Hashimoto H; Kubota M; Shimizu T; Kasai Y; Sano H; Adachi S; Akiyama Y; Mikawa H
Leukemia; 1992 Nov; 6(11):1199-202. PubMed ID: 1434805
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
15. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
16. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
17. [High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children].
Makhonova LA; Maiakova SA; Kiselev AV; Gordina GA; Balakirev SA; Gavrilova IE; Moiseenko EI; Morozova OV
Vopr Onkol; 1990; 36(10):1196-200. PubMed ID: 2251813
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
19. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
